OLA
CRL icon

Oliver Luxxe Assets’s Charles River Laboratories CRL Stock Holding History

Oliver Luxxe Assets’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,284
Closed -$2.05M – 206
2025
Q4 		$2.05M Buy
+10,284
New +$1.87M 0.31% 113
2021
Q1 		– Sell
-5,317
Closed -$1.47M – 179
2020
Q4 		$1.47M Buy
5,317
+3,802
+251% +$905K 0.46% 81
2020
Q3 		$343K Sell
1,515
-12
-0.8% -$2.49K 0.13% 123
2020
Q2 		$266K Hold
1,527
– – 0.14% 107
2020
Q1 		$216K Buy
+1,527
New +$229K 0.14% 110

Other funds holding CRL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Oliver Luxxe Assets's CRL Position: Q1 2026 in Review

Oliver Luxxe Assets sold out of Charles River Laboratories (CRL) in Q1 2026, closing a stake of 10,284 shares — an estimated $2.05M sold.

Oliver Luxxe Assets first reported a position in CRL in Q1 2020 and held it in 5 quarters. The position peaked at $2.05M in Q4 2025. 560 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Oliver Luxxe Assets reported no remaining Charles River Laboratories position as of Q1 2026 after selling out during the quarter.
  • Oliver Luxxe Assets sold 10,284 Charles River Laboratories shares in Q1 2026, an estimated $2.05M.
  • Oliver Luxxe Assets first reported a position in Charles River Laboratories in Q1 2020 and held it in 5 quarters.
  • Oliver Luxxe Assets's Charles River Laboratories position peaked at $2.05M in Q4 2025.
  • 560 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Oliver Luxxe Assets's 13F filing for Q1 2026, filed 8 Apr 2026.